Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis

More on Lipid and ceramide metabolism

• Estimated sdLDL-C predicts cardiovascular risk in Japanese adults

  Journal of Clinical Lipidology · 4 Oct 2026

• Risk factors for atherosclerosis diverge across vascular beds

  American Journal of Preventive Cardiology · 4 Oct 2026

  

• Cumulative non-HDL cholesterol is linked to CVD risk

  Journal of Diabetes and Metabolic Disorders · 4 Oct 2026

• Mild caloric restriction accelerates atherosclerosis in mice

  JCI Insight · 4 Oct 2026